Suzhou Connect Biopharmaceuticals

Discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation

placeSuzhou, Jiangsu, China calendar_todayFounded 2012 groups100 employees language connectbiopharm.com

Innovation

11 patent families (5 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 382 times.

YearFilings
20151
20163
20172
20184
20194
20204
20216
20225
20237
20243
20253

Investor mix

12 investors on record; lead investors include RA Capital Management, Qiming Venture Partners, Advantech Capital, Cowin Capital; 1 has since exited.

Investor typeCountShare
Venture capital867%
Private equity217%
Other / undisclosed217%
Coming soon